Facebook
Twitter
LinkedIn
ForwardThe Intersection of Viral Hepatitis and the Opioid Epidemic West Virgina
The goal of this course module is to help clinicians and other service providers understand the local and regional picture of viral hepatitis, understand HCV screening recommendations, current treatment options, and specific issues with vulnerable populations especially people who inject drugs, the opioid use disorder.
Target Audience
This program is directed to primary care physicians, specialists (ID, Gastro, Hepatology), nurses, public health, Drug and Alcohol counselors, care coordinators, advocates and other allied health care workers involved in the healthcare of patients who have risk factors for Hepatitis C particularly people who use drugs.
Learning Objectives
At course completion, attendees should be able to:
Performance
Increase HCV testing (national average is 48%, goal is 66%) in Pennsylvania
Competency
Successful linkage to HCV care will increase. Providers will understand the intersection of the three epidemics (OUD, OD, ID)
Increase Knowledge
Understand the effectiveness and efficacy of harm reduction strategies for community health.
Additional Information
| Attachment | Size |
|---|---|
 CLA West Virginia Intersection Program Agenda (approved).pdf | 142.4 KB |
Schedule
Registration/Networking/Exhibits/Refreshments
10:00 a.m.
Welcome
Suzanna Masartis
Executive Director
Community Liver Alliance
Sherri Ferrell, MBA
CEO
West Virginia Primary Care Association
10:10 a.m.
The Role of Peer-To-Peer Harm Reduction in Injection Drug Use
Shannon Hicks
Executive Director
Exchange Union
10:30am
Challenges in Addressing HCV in PWID: Insights from Appalachian Ohio and West Virginia
Judith Feinberg, MD
Professor of Behavioral Medicine & Psychiatry
WVU Medicine
11:15am
Screening, Diagnosis and Treatment of Hep C in Primary Care
Greg Peters, MD Community Care of West Virginia
Letitia Tierney MD, Cabin Creek Health Center
Jennifer Boyd, PA-C New River Health Center
Matt Weimer, MD Valley Health System
12:15 p.m.
Lunch/Networking
Viral Hepatitis in West Virginia Update
Maria del Rosario, MD, MPH
Director of Surveillance
West Virginia Department of Health and Human Resources
1:30 p.m.
Harm Reduction Strategies-More Than Syringe Exchange
Mike Sellick, MSW
Hepatitis C Training and Policy Manager
Harm Reduction Coalition
2:00 p.m.
A Community Health Center’s Response to an HIV Cluster
Matt Weimer, MD
Valley Health System
2:45pm
Screening for Viral Hepatitis and HIV (No CME credit awarded)
Dusica (Dee) Curanovic, PhD
Medical Science Liaison
LabCorp and Monogram Biosciences
3:15pm
HepConnect Update (No CME credit awarded)
Arun Skaria
Director, Corporate Contributions
Public Affairs
Gilead Sciences, Inc.
3:45 p.m.
Where Do We Go From Here?
Sherri Ferrell, MBA
CEO
West Virginia Primary Care Association
4:00 p.m.
Adjourn
Faculty Listing
Suzanna Masartis
Executive Director
Community Liver Alliance
Pittsburgh, PA
Sherri Ferrell, MBA
CEO
West Virginia Primary Care Association
Charleston, WV
Shannon Hicks
Executive Director
Exchange Union
Jefferson County, WV
Judith Feinberg, MD
Professor of Behavioral Medicine & Psychiatry
WVU Medicine
Morgantown, WV
Greg Peters, MD
Community Care of West Virginia
Buckhannon WV
Letitia Tierney MD
Cabin Creek Health Center
Dawes, WV
Jennifer Boyd, PA-C
New River Health Center
Fayetteville, WV
Matt Weimer, MD
Valley Health System
Milton, WV
Maria del Rosario, MD, MPH
Director of Surveillance
West Virginia Department of Health and Human Resources
Wheeling, WV
Mike Sellick, MSW
Hepatitis C Training and Policy Manager
Harm Reduction Coalition
New York, NY
Other:
Arun Skaria
Director, Corporate Contributions
Public Affairs
Gilead Sciences, Inc.
Foster City, CA
Dusica (Dee) Curanovic, PhD
Medical Science Liaison
LabCorp and Monogram Biosciences
Burlington, NC
All individuals in a position to control the content of this education activity including members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.
The following relevant financial relationships were disclosed:
Mike Selick, MSW – Grant Research Support from Gilead Sciences.
No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
In support of improving patient care, this activity has been planned and implemented by the University of Pittsburgh and the Community Liver Alliance. The University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Pittsburgh School of Medicine designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Available Credit
- 4.25 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 4.25 Attendance